

Efficacy and safety results from the randomized controlled trial of adalimumab vs. methotrexate vs. placebo in patients with

British Journal of Dermatology

158, 558-566

DOI: [10.1111/j.1365-2133.2007.08315.x](https://doi.org/10.1111/j.1365-2133.2007.08315.x)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 2 | From conventional to cutting edge: the new era of biologics in treatment of psoriasis. <i>Dermatologic Therapy</i> , 2008, 21, 131-141. | 0.8 | 38 |
| 3 | Adalimumab: a new alternative biologic agent for chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2008, 158, 435-436. | 1.4 | 6 |
| 5 | Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2008, 159, 257-258. | 1.4 | 7 |
| 6 | Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2008, 159, 513-526. | 1.4 | 182 |
| 7 | Long-term data in the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2008, 159, 18-24. | 1.4 | 28 |
| 8 | Methotrexate for psoriasis in the era of biological therapy. <i>Clinical and Experimental Dermatology</i> , 2008, 33, 551-554. | 0.6 | 61 |
| 9 | Adalimumab in dermatology. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 618-625. | 1.1 | 33 |
| 10 | Etanercept provides a more physiological approach in the treatment of psoriasis. <i>Dermatologic Therapy</i> , 2008, 21, S1-S14. | 0.8 | 9 |
| 11 | National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 209-217. | 0.6 | 157 |
| 12 | Tratamiento de la psoriasis moderada y grave con adalimumab. <i>Piel</i> , 2008, 23, 577-581. | 0.0 | 1 |
| 14 | Targeting tumor necrosis factor $\hat{\pm}$ in psoriasis and psoriatic arthritis. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1085-1096. | 1.5 | 58 |
| 15 | Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis. <i>Dermatology</i> , 2008, 216, 260-270. | 0.9 | 104 |
| 17 | Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics. <i>Yearbook of Dermatology and Dermatologic Surgery</i> , 2008, 2008, 97-99. | 0.0 | 0 |
| 18 | Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). <i>Yearbook of Dermatology and Dermatologic Surgery</i> , 2008, 2008, 100-101. | 0.0 | 0 |
| 19 | Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2009, 2, 95. | 0.8 | 0 |
| 20 | Biologics in the management of psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2009, 2, 111. | 0.8 | 8 |
| 21 | A Short Cycle of Narrow-Band UVB Phototherapy in the Early Phase of Long-Term Efalizumab Can Provide a Quicker Remission of Moderate and Severe Psoriasis: A Pilot Study. <i>Dermatology</i> , 2009, 218, 321-326. | 0.9 | 14 |
| 22 | Marked Improvement in Nail Psoriasis during Treatment with Adalimumab. <i>Dermatology</i> , 2009, 219, 353-356. | 0.9 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 23 | A Multicenter Open-Label Experience on the Response of Psoriasis to Adalimumab and Effect of Dose Escalation in Non-Responders: The Aphrodite Project. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 227-233. | 1.0 | 10 |
| 24 | Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2009, 219, 209-218. | 0.9 | 87 |
| 25 | Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). <i>BMJ: British Medical Journal</i> , 2009, 338, b1542-b1542. | 2.4 | 102 |
| 26 | Psoriasis Comorbidities. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S77-S87. | 0.6 | 35 |
| 27 | Biologics in the Treatment of Psoriasis: Clinical and Economic Overview. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S49-S57. | 0.6 | 22 |
| 28 | Cytokines and Cytokine Profiles in Human Autoimmune Diseases and Animal Models of Autoimmunity. <i>Mediators of Inflammation</i> , 2009, 2009, 1-20. | 1.4 | 131 |
| 29 | Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S58-S66. | 0.6 | 19 |
| 30 | Acute bilateral phrenic neuropathy following treatment with adalimumab. <i>Clinical Rheumatology</i> , 2009, 28, 1337-1340. | 1.0 | 15 |
| 32 | Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis. <i>International Journal of Dermatology</i> , 2009, 48, 653-658. | 0.5 | 19 |
| 33 | Economic evaluation of systemic therapies for moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2009, 160, 1264-1272. | 1.4 | 73 |
| 34 | Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 784-788. | 0.6 | 26 |
| 35 | What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 664-667. | 0.6 | 7 |
| 36 | Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?. <i>Dermatologic Therapy</i> , 2009, 22, 431-440. | 0.8 | 40 |
| 37 | Emerging drugs for psoriasis. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 145-163. | 1.0 | 7 |
| 38 | Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 277-286. | 0.2 | 95 |
| 39 | Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 386-413. | 0.2 | 73 |
| 40 | Eficiencia de los agentes biológicos en el tratamiento de la psoriasis moderada-grave. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 792-803. | 0.2 | 19 |
| 41 | Cutaneous side effects of anti-tumor necrosis factor biologic therapy: A clinical review. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 486-504. | 0.6 | 166 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 42 | Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 824-837. | 0.6 | 289 |
| 43 | Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 451-485. | 0.6 | 505 |
| 45 | Psoriasis. <i>New England Journal of Medicine</i> , 2009, 361, 496-509. | 13.9 | 2,498 |
| 46 | Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiliográficas</i> , 2009, 100, 277-288. | 0.2 | 11 |
| 47 | Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. <i>Actas Dermo-sifiliográficas</i> , 2009, 100, 386-413. | 0.2 | 14 |
| 48 | Efficiency of Biologic Agents in the Treatment of Moderate to Severe Psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2009, 100, 792-803. | 0.2 | 4 |
| 49 | Nail Psoriasis. <i>Drugs</i> , 2009, 69, 2351-2361. | 4.9 | 35 |
| 50 | Adalimumab: a guide to its use in plaque psoriasis. <i>Drugs and Therapy Perspectives</i> , 2009, 25, 6-9. | 0.3 | 0 |
| 51 | Adalimumab. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 43-50. | 3.3 | 14 |
| 52 | Efalizumab. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 51-72. | 3.3 | 29 |
| 56 | Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). <i>Yearbook of Dermatology and Dermatologic Surgery</i> , 2009, 2009, 143-145. | 0.0 | 0 |
| 57 | Cost-effectiveness analysis of TNF- α blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. <i>Dermatologic Therapy</i> , 2010, 23, S7-S13. | 0.8 | 17 |
| 58 | Treatment of nail psoriasis with adalimumab: an open label unblinded study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 530-534. | 1.3 | 77 |
| 59 | Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1135-1143. | 1.3 | 28 |
| 60 | Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1447-1451. | 1.3 | 49 |
| 61 | EADV preceptorship: advances in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 2-24. | 1.3 | 11 |
| 62 | Comparing biological therapies in psoriasis: implications for clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 10-14. | 1.3 | 26 |
| 63 | Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. <i>British Journal of Pharmacology</i> , 2010, 160, 810-820. | 2.7 | 120 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 64 | Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study. <i>Journal of Dermatology</i> , 2010, 37, 299-310. | 0.6 | 169 |
| 66 | Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006. <i>British Journal of Dermatology</i> , 2010, 162, 384-389. | 1.4 | 34 |
| 67 | Using "number needed to treat"™ to express the magnitudes of benefit of ultraviolet B phototherapy and of antitumour necrosis factor- α therapies for psoriasis. <i>British Journal of Dermatology</i> , 2010, 162, 456-457. | 1.4 | 4 |
| 68 | British Journal of Dermatology : a fresh complexion. <i>British Journal of Dermatology</i> , 2010, 162, 1-3. | 1.4 | 2 |
| 69 | Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. <i>British Journal of Dermatology</i> , 2010, 162, 1216-1223. | 1.4 | 31 |
| 70 | Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2010, 162, 1349-1358. | 1.4 | 39 |
| 71 | A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. <i>British Journal of Dermatology</i> , 2010, 163, 402-411. | 1.4 | 99 |
| 72 | Tumour necrosis factor- α blockers in the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2010, 162, 1169-1171. | 1.4 | 1 |
| 73 | Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. <i>British Journal of Dermatology</i> , 2010, 163, 889-892. | 1.4 | 21 |
| 74 | Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. <i>British Journal of Dermatology</i> , 2010, 163, 838-846. | 1.4 | 45 |
| 75 | Update of the management of chronic psoriasis: new approaches and emerging treatment options. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2010, 3, 25. | 0.8 | 4 |
| 78 | Guidelines on the Management of Psoriasis in South Africa. <i>South African Medical Journal</i> , 2010, 100, 255. | 0.2 | 19 |
| 79 | A Review of the Efficacy and Safety of Combined Methotrexate and Ultraviolet B Phototherapy versus Ultraviolet B Phototherapy Alone in the Treatment of Psoriasis. <i>Psoriasis Forum</i> , 2010, 16a, 26-32. | 0.1 | 0 |
| 80 | The psoriasiform reaction pattern. , 2010, , 71-91.e18. | | 4 |
| 81 | Interleukin 4 or Cytokine Antagonists? Time to Change the Search for Novel Psoriasis Therapies. <i>Dermatology</i> , 2010, 221, 27-29. | 0.9 | 4 |
| 82 | Psoriasis Care: New and Emerging Pharmacologic Trends. <i>Journal of Cutaneous Medicine and Surgery</i> , 2010, 14, 119-129. | 0.6 | 8 |
| 83 | Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis. <i>Dermatology</i> , 2010, 221, 236-242. | 0.9 | 21 |
| 84 | Clinically validated approaches to the treatment of autoimmune diseases. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 195-213. | 1.9 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 85 | Psoriasis: What is new in nonbiologic systemic therapy in the era of biologics?. Indian Journal of Dermatology, Venereology and Leprology, 2010, 76, 622. | 0.2 | 13 |
| 86 | Impact of Adalimumab on Symptoms of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A Pooled Analysis of Randomized Clinical Trials. Dermatology, 2010, 220, 1-7. | 0.9 | 20 |
| 87 | Psoriasis and its treatment with adalimumab. Expert Opinion on Biological Therapy, 2010, 10, 133-152. | 1.4 | 5 |
| 90 | Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. New England Journal of Medicine, 2010, 362, 118-128. | 13.9 | 773 |
| 91 | The therapeutic potential of TNF- α antagonists for skin psoriasis comorbidities. Expert Opinion on Biological Therapy, 2010, 10, 1197-1208. | 1.4 | 19 |
| 92 | Adverse Reactions During Biological Therapy for Psoriasis: Results of a Survey of the Spanish Psoriasis Group. Actas Dermo-sifiligráficas, 2010, 101, 156-163. | 0.2 | 1 |
| 93 | Guidelines on the Use of Methotrexate in Psoriasis. Actas Dermo-sifiligráficas, 2010, 101, 600-613. | 0.2 | 10 |
| 94 | Treatment of Scalp Psoriasis: Review of the Evidence and Delphi Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermo-sifiligráficas, 2010, 101, 827-846. | 0.2 | 6 |
| 95 | Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. Journal of the American Academy of Dermatology, 2010, 63, 228-234. | 0.6 | 46 |
| 96 | Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: Comparison of adverse event-free response days in the CHAMPION trial. Journal of the American Academy of Dermatology, 2010, 63, 1011-1018. | 0.6 | 32 |
| 97 | A new era in the management of psoriasis? The biologics: facts and controversies. Clinics in Dermatology, 2010, 28, 81-87. | 0.8 | 30 |
| 98 | Safety and Efficacy of the Tumor Necrosis Factor Antagonists. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 35-47. | 1.6 | 36 |
| 99 | Metotrexato: guía de uso en psoriasis. Actas Dermo-sifiligráficas, 2010, 101, 600-613. | 0.2 | 65 |
| 100 | Tratamiento de la psoriasis del cuero cabelludo. Revisión de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. Actas Dermo-sifiligráficas, 2010, 101, 827-846. | 0.2 | 13 |
| 101 | Coronary Heart Disease and Stroke Risk in Patients with Psoriasis: Retrospective Analysis. American Journal of Medicine, 2010, 123, 350-357. | 0.6 | 92 |
| 103 | Comparative Effectiveness Without Head-to-Head Trials. Pharmacoeconomics, 2010, 28, 935-945. | 1.7 | 247 |
| 104 | Advances in the treatment of moderate-to-severe plaque psoriasis. American Journal of Health-System Pharmacy, 2011, 68, 795-806. | 0.5 | 27 |
| 105 | Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities. American Journal of Clinical Dermatology, 2011, 12, 51-62. | 3.3 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 106 | Adalimumab or Cyclosporine as Monotherapy and in Combination in Severe Psoriatic Arthritis: Results from a Prospective 12-month Nonrandomized Unblinded Clinical Trial. <i>Journal of Rheumatology</i> , 2011, 38, 2466-2474. | 1.0 | 52 |
| 107 | Quality of Life in Patients with Immune-Mediated Inflammatory Diseases. <i>Journal of rheumatology Supplement, The</i> , 2011, 88, 7-19. | 2.2 | 20 |
| 110 | The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 9-13. | 1.3 | 40 |
| 111 | Effects of Adalimumab versus Placebo on Risk of Symptom Worsening in Psoriasis and Subsequent Impacts on Health-Related Quality-of-Life. <i>Clinical Drug Investigation</i> , 2011, 31, 51-60. | 1.1 | 13 |
| 112 | The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 321-337. | 3.3 | 62 |
| 113 | Effects of Thai Medicinal Herb Extracts with Anti-Psoriatic Activity on the Expression on NF- κ B Signaling Biomarkers in HaCaT Keratinocytes. <i>Molecules</i> , 2011, 16, 3908-3932. | 1.7 | 57 |
| 114 | Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 671-681. | 0.6 | 69 |
| 115 | The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1035-1050. | 0.6 | 197 |
| 116 | Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 137-174. | 0.6 | 398 |
| 117 | Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2011, 165, 661-668. | 1.4 | 128 |
| 118 | Adverse effects of biologics: a network meta-analysis and Cochrane overview. <i>The Cochrane Library</i> , 2016, 2016, CD008794. | 1.5 | 481 |
| 119 | A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2041-2054. | 0.9 | 56 |
| 120 | Efficacy and Safety of a Second Adalimumab Treatment Cycle in Psoriasis Patients who Relapsed after Adalimumab Discontinuation or Dosage Reduction: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Psoriasis Forum</i> , 2011, 17a, 88-96. | 0.1 | 6 |
| 123 | Psoriasis associated with anti-tumor necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1318-1327. | 1.9 | 177 |
| 124 | Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. <i>British Journal of Dermatology</i> , 2011, 164, 434-441. | 1.4 | 98 |
| 125 | Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. <i>British Journal of Dermatology</i> , 2011, 165, 640-645. | 1.4 | 51 |
| 126 | Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. <i>British Journal of Dermatology</i> , 2011, 165, 399-406. | 1.4 | 45 |
| 127 | Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2011, 165, 652-660. | 1.4 | 120 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 128 | Methotrexate, a drug for the years to come. <i>British Journal of Dermatology</i> , 2011, 165, 230-231. | 1.4 | 0 |
| 129 | Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). <i>British Journal of Dermatology</i> , 2011, 165, 1109-1117. | 1.4 | 159 |
| 130 | Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1012-1020. | 1.3 | 47 |
| 131 | Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 12-18. | 1.3 | 135 |
| 132 | 311-nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2011, 27, 186-189. | 0.7 | 42 |
| 134 | Ajuste de dosis en psoriasis tratadas con adalimumab. <i>Piel</i> , 2011, 26, 358-360. | 0.0 | 2 |
| 135 | Atorvastatin for the Treatment of Plaque-Type Psoriasis. <i>Pharmacotherapy</i> , 2011, 31, 1045-1050. | 1.2 | 23 |
| 136 | Definition of treatment goals for moderate to severe psoriasis: a European consensus. <i>Archives of Dermatological Research</i> , 2011, 303, 1-10. | 1.1 | 690 |
| 137 | Anti-tumor necrosis factor- α therapies for immune-mediated and inflammatory skin diseases. <i>Drug Development Research</i> , 2011, 72, 615-622. | 1.4 | 1 |
| 138 | Topical Psoriasis Therapy in the Age of Biologics: Evidence-Based Treatment Recommendations. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 309-321. | 0.6 | 11 |
| 139 | A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis. <i>New England Journal of Medicine</i> , 2011, 365, 1586-1596. | 13.9 | 182 |
| 140 | Canadian Guidelines for the Management of Plaque Psoriasis: Overview. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 210-219. | 0.6 | 76 |
| 141 | Summary of Minutes of the GRAPPA Meeting Adjacent to the American Academy of Dermatology 67th Annual Meeting: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 553-556. | 1.0 | 2 |
| 142 | Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2011, 22, 65-74. | 1.1 | 32 |
| 143 | Acitretin revisited in the era of biologics. <i>Journal of Dermatological Treatment</i> , 2011, 22, 86-89. | 1.1 | 37 |
| 144 | Are Treatment Satisfaction, Quality of Life, and Self-assessed Disease Severity Relevant Parameters for Patient Registries? Experiences from Finnish and Swedish Patients with Psoriasis. <i>Acta Dermato-Venereologica</i> , 2011, 91, 409-414. | 0.6 | 16 |
| 145 | Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet. <i>Archives of Dermatology</i> , 2011, 147, 429. | 1.7 | 96 |
| 146 | Discontinuation of Methotrexate in Psoriasis. <i>Acta Dermato-Venereologica</i> , 2012, 92, 353-354. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 147 | A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 304-314. | 0.3 | 157 |
| 148 | Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice Setting. <i>Archives of Dermatology</i> , 2012, 148, 487. | 1.7 | 81 |
| 149 | Putting together the psoriasis puzzle: an update on developing targeted therapies. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 423-433. | 1.2 | 111 |
| 150 | Briakinumab versus Methotrexate for Psoriasis. <i>New England Journal of Medicine</i> , 2012, 366, 379-380. | 13.9 | 4 |
| 151 | Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. <i>Journal of Rheumatology</i> , 2012, 39, 63-72. | 1.0 | 58 |
| 153 | Psoriasis, a proof-of-principle condition for immune-mediated inflammatory disorders: perspectives toward optimal clinical trial design. <i>Clinical Investigation</i> , 2012, 2, 671-678. | 0.0 | 0 |
| 154 | A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2012, 167, 649-657. | 1.4 | 116 |
| 155 | Efficacy, safety and medication cost implications of adalimumab 40mg weekly dosing in patients with psoriasis with suboptimal response to 40mg every other week dosing: results from an open-label study. <i>British Journal of Dermatology</i> , 2012, 167, 658-667. | 1.4 | 44 |
| 156 | Ethical considerations when prescribing biologics in dermatology. <i>Clinics in Dermatology</i> , 2012, 30, 492-495. | 0.8 | 4 |
| 157 | Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. <i>Dermatology and Therapy</i> , 2012, 2, 9. | 1.4 | 29 |
| 158 | Nonserious Infections. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 707-725. | 0.8 | 16 |
| 159 | Therapy for Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 583-600. | 0.8 | 8 |
| 160 | A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin. <i>Dermatology</i> , 2012, 225, 298-303. | 0.9 | 13 |
| 161 | Efficacy of adalimumab in the treatment of psoriasis: A retrospective study of 15 patients in daily practice. <i>Journal of Dermatological Treatment</i> , 2012, 23, 203-207. | 1.1 | 25 |
| 162 | The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, e67-e76. | 0.6 | 62 |
| 163 | Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 241-251. | 0.6 | 157 |
| 164 | Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 369-375. | 0.6 | 158 |
| 165 | Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 376-386. | 0.6 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 166 | Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 731-741. | 0.6 | 101 |
| 167 | Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 1403. | 1.7 | 64 |
| 168 | Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIb trial. <i>British Journal of Dermatology</i> , 2012, 167, 1374-1381. | 1.4 | 59 |
| 169 | Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. <i>British Journal of Dermatology</i> , 2012, 166, 861-872. | 1.4 | 121 |
| 170 | Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2012, 167, 12-20. | 1.4 | 38 |
| 171 | Current and Emerging Systemic Treatment Strategies for Psoriasis. <i>Drugs</i> , 2012, 72, 1867-1880. | 4.9 | 35 |
| 172 | Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research. <i>Value in Health</i> , 2012, 15, 940-947. | 0.1 | 290 |
| 173 | Cost Per Responder Associated with Biologic Therapies for Crohn's Disease, Psoriasis, and Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2012, 29, 620-634. | 1.3 | 56 |
| 174 | Nail Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 375-388. | 3.3 | 83 |
| 175 | Consensus Guidelines for the Management of Plaque Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 95. | 1.7 | 148 |
| 176 | Comparative Efficacy of Biologics in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 365-374. | 3.3 | 52 |
| 177 | The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. <i>Open Access Rheumatology: Research and Reviews</i> , 2012, 4, 33. | 0.8 | 4 |
| 178 | Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 261. | 0.7 | 14 |
| 179 | History of Methotrexate and Use in Psoriasis. <i>Psoriasis Forum</i> , 2012, 18a, 164-173. | 0.1 | 1 |
| 180 | Biologics in the treatment of psoriasis and emerging new therapies in the pipeline. <i>Psoriasis: Targets and Therapy</i> , 2012, , 29. | 1.2 | 2 |
| 181 | Psoriasis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2012, 7, 385-422. | 9.6 | 412 |
| 182 | A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. <i>Dermatology and Therapy</i> , 2012, 2, 1. | 1.4 | 18 |
| 183 | A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. <i>Dermatology and Therapy</i> , 2012, 2, 2. | 1.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 184 | Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. <i>European Journal of Health Economics</i> , 2012, 13, 145-156. | 1.4 | 17 |
| 185 | Do men have more severe psoriasis than women?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 126-127. | 1.3 | 17 |
| 186 | Management of moderate to severe psoriasis with systemic immunomodulatory therapies: a 5-year experience from two departments of dermatology of Northern France. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1038-1039. | 1.3 | 1 |
| 187 | The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 991-998. | 1.3 | 17 |
| 188 | Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1007-1013. | 1.3 | 14 |
| 189 | Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1298-1303. | 1.3 | 13 |
| 190 | Cost-effectiveness of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 768-777. | 1.3 | 31 |
| 191 | The concept of psoriasis as a systemic inflammation: implications for disease management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 3-11. | 1.3 | 253 |
| 192 | Implementing treatment goals for successful long-term management of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 12-20. | 1.3 | 70 |
| 193 | Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 21-29. | 1.3 | 21 |
| 194 | Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2012, 166, 179-188. | 1.4 | 177 |
| 195 | S3 " Guidelines on the treatment of psoriasis vulgaris (English version). Update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, S1-95. | 0.4 | 235 |
| 196 | Methotrexate therapy in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 363-370. | 0.4 | 1 |
| 197 | Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: Results in a single community-based hospital. <i>Journal of Dermatology</i> , 2012, 39, 265-268. | 0.6 | 14 |
| 198 | Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1175-1180. | 1.9 | 22 |
| 199 | Differing patterns of methotrexate use for psoriatic disease among dermatologists and rheumatologists. <i>British Journal of Dermatology</i> , 2012, 167, 448-450. | 1.4 | 8 |
| 200 | Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study. <i>British Journal of Dermatology</i> , 2012, 167, 165-173. | 1.4 | 21 |
| 201 | Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab ² certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. <i>British Journal of Dermatology</i> , 2012, 167, 180-190. | 1.4 | 131 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 202 | German S3-guidelines on the treatment of psoriasis vulgaris (short version). Archives of Dermatological Research, 2012, 304, 87-113. | 1.1 | 96 |
| 203 | Etanercept use for psoriasis in Taiwan: a case series study. International Journal of Dermatology, 2013, 52, 673-680. | 0.5 | 7 |
| 204 | Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 593-600. | 1.3 | 32 |
| 205 | Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 634-642. | 1.3 | 46 |
| 206 | Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. Journal of Dermatological Treatment, 2013, 24, 193-198. | 1.1 | 38 |
| 207 | Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 861-866. | 1.3 | 36 |
| 208 | An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1444-1447. | 1.3 | 14 |
| 209 | Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. American Journal of Clinical Dermatology, 2013, 14, 315-326. | 3.3 | 55 |
| 210 | Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring. Clinical Reviews in Allergy and Immunology, 2013, 44, 121-140. | 2.9 | 69 |
| 211 | Systemic methotrexate therapy for psoriasis: past, present and future. Clinical and Experimental Dermatology, 2013, 38, 573-588. | 0.6 | 54 |
| 212 | Psoriasis, Anti-Tumor Necrosis Factor Therapy, and Tuberculosis: Report of Three Challenging Cases and Literature Review. Infectious Diseases and Therapy, 2013, 2, 59-73. | 1.8 | 10 |
| 214 | Biological therapies for psoriasis. Expert Opinion on Biological Therapy, 2013, 13, 1715-1730. | 1.4 | 23 |
| 215 | Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis. Journal of the American Academy of Dermatology, 2013, 68, 609-617. | 0.6 | 115 |
| 216 | Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. Journal of Dermatological Treatment, 2013, 24, 351-355. | 1.1 | 17 |
| 217 | Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. Expert Opinion on Biological Therapy, 2013, 13, 1325-1334. | 1.4 | 9 |
| 218 | The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends in Immunology, 2013, 34, 174-181. | 2.9 | 399 |
| 220 | Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. Actas Dermo-sifiligráficas, 2013, 104, 694-709. | 0.2 | 32 |
| 221 | Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept. Dermatologica Sinica, 2013, 31, 11-18. | 0.2 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 222 | An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. <i>British Journal of Dermatology</i> , 2013, 168, 374-380. | 1.4 | 16 |
| 223 | Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 64-72. | 0.6 | 107 |
| 224 | Biological treatments for moderate-to-severe psoriasis: indirect comparison. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 121-130. | 0.7 | 37 |
| 225 | Treatment of Psoriasis and Psoriatic Arthritis. <i>BioDrugs</i> , 2013, 27, 3-12. | 2.2 | 42 |
| 226 | Which Antipsoriatic Drug Has the Fastest Onset of Action?â€”Systematic Review on the Rapidity of the Onset of Action. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1963-1970. | 0.3 | 57 |
| 227 | Using Hawthorne Effects to Improve Adherence in Clinical Practice: Lessons From Clinical Trialsâ€”Reply. <i>JAMA Dermatology</i> , 2013, 149, 490. | 2.0 | 5 |
| 228 | Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. <i>British Journal of Dermatology</i> , 2013, 169, 1141-1147. | 1.4 | 46 |
| 229 | Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. <i>Australasian Journal of Dermatology</i> , 2013, 54, 259-263. | 0.4 | 41 |
| 230 | Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e376-83. | 1.3 | 93 |
| 231 | A costly revolution for a subgroup of patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2013, 168, 467-470. | 1.4 | 3 |
| 232 | <sc>TNF</sc> and <sc>IL</sc>-17A-mediated S100A8 expression is regulated by p38 <sc>MAPK</sc>. <i>Experimental Dermatology</i> , 2013, 22, 476-481. | 1.4 | 34 |
| 233 | Dose Response and Pharmacokinetics of Tofacitinib (CPâ€690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-8. | 1.3 | 4 |
| 234 | Incomplete Data in Randomized Dermatology Trials: Consequences and Statistical Methodology. <i>Dermatology</i> , 2013, 226, 19-27. | 0.9 | 6 |
| 236 | Immunotargeting in the management of psoriasis. <i>ImmunoTargets and Therapy</i> , 2013, 2, 51. | 2.7 | 2 |
| 237 | Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials. <i>Cadernos De Saude Publica</i> , 2013, 29, s17-s31. | 0.4 | 4 |
| 238 | Tuberculosis Reactivation Risk in Dermatology. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 65-70. | 2.2 | 9 |
| 239 | Induction or Exacerbation of Psoriasis in Patients with Crohn's Disease under Treatment with Anti-TNF Antibodies. <i>Digestion</i> , 2014, 89, 209-215. | 1.2 | 18 |
| 240 | Unmet needs in the treatment of psoriasis. <i>European Journal of Dermatology</i> , 2014, 24, 523-532. | 0.3 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 242 | Adalimumab in the Treatment of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 33-48. | 1.0 | 65 |
| 243 | Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 11-32. | 1.0 | 50 |
| 244 | The outstanding record of clinical trials in the <i>British Journal of Dermatology</i> . <i>British Journal of Dermatology</i> , 2014, 170, 761-763. | 1.4 | 3 |
| 245 | The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 846-852. | 1.3 | 58 |
| 246 | Prospective registration of clinical trials published in the <i>British Journal of Dermatology</i> . <i>British Journal of Dermatology</i> , 2014, 171, 681-683. | 1.4 | 7 |
| 247 | Do we need a patient satisfaction score?. <i>British Journal of Dermatology</i> , 2014, 170, 494-495. | 1.4 | 2 |
| 248 | Efficacy of adalimumab across subgroups of patients with moderate to severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 882-890. | 1.3 | 36 |
| 249 | Efficacy of biologics in the treatment of moderate to severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1633-1653. | 1.3 | 65 |
| 250 | TNF-induced leukocyte endothelial cell interactions show marked interindividual differences independent of the clinical response to adalimumab. <i>Experimental Dermatology</i> , 2014, 23, 133-135. | 1.4 | 6 |
| 251 | Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada. <i>Journal of Cutaneous Medicine and Surgery</i> , 2014, 18, 371-378. | 0.6 | 14 |
| 252 | Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis. <i>Psoriasis: Targets and Therapy</i> , 0, , 11. | 1.2 | 0 |
| 253 | The possibilities and principles of methotrexate treatment of psoriasis – the updated knowledge. <i>Postepy Dermatologii i Alergologii</i> , 2014, 6, 392-400. | 0.4 | 66 |
| 254 | Serum Levels of TNF- α , IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9. | 0.9 | 55 |
| 255 | Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2014, 150, 130. | 2.0 | 76 |
| 256 | Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. <i>Drugs</i> , 2014, 74, 423-441. | 4.9 | 209 |
| 257 | Cost-effectiveness of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system. <i>International Journal of Dermatology</i> , 2014, 53, 1151-1156. | 0.5 | 13 |
| 258 | Methotrexate: New Therapeutic Approaches. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 583-589. | 0.2 | 16 |
| 259 | Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice. <i>European Journal of Dermatology</i> , 2014, 24, 217-223. | 0.3 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 260 | Psoriasis. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015354-a015354. | 2.9 | 233 |
| 261 | ¿C3mo comparar fármacos biológicos?. Reumatología Clínica, 2014, 10, 353-359. | 0.2 | 4 |
| 262 | Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Annals of Medicine, 2014, 46, 547-554. | 1.5 | 93 |
| 263 | Newer agents for psoriasis in adults. BMJ, The, 2014, 349, g4026-g4026. | 3.0 | 5 |
| 264 | Treating moderate to severe psoriasis – best use of biologics. Expert Review of Clinical Immunology, 2014, 10, 269-279. | 1.3 | 24 |
| 265 | A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 438-453. | 1.3 | 122 |
| 266 | The risk of deep fungal infections during biologic therapy for psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1277-1285. | 1.3 | 7 |
| 267 | How to Compare Biologic Drugs. Reumatología Clínica (English Edition), 2014, 10, 353-359. | 0.2 | 0 |
| 268 | Metotrexato: novedades terapéuticas. Actas Dermo-sifiligráficas, 2014, 105, 583-589. | 0.2 | 30 |
| 269 | Picea mariana polyphenolic extract inhibits proinflammatory mediators produced by TNF- α -activated psoriatic keratinocytes: Impact on NF- κ B pathway. Journal of Ethnopharmacology, 2014, 151, 265-278. | 2.0 | 22 |
| 270 | Estudio retrospectivo de la eficacia y seguridad de adalimumab en el tratamiento de la psoriasis en la práctica clínica diaria. Piel, 2014, 29, 468-476. | 0.0 | 0 |
| 272 | What does the BJD now stand for? A position statement. British Journal of Dermatology, 2015, 172, 1463-1465. | 1.4 | 16 |
| 273 | Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. British Journal of Dermatology, 2015, 173, 949-961. | 1.4 | 253 |
| 274 | Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. British Journal of Dermatology, 2015, 173, 510-518. | 1.4 | 87 |
| 275 | An updated survey for the 2007-2013 period of randomized controlled trials for psoriasis: treatment modalities, study designs, comparators, outcome measures and sponsorship. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1945-1950. | 1.3 | 5 |
| 276 | Th17 Cells in Type 1 Diabetes: Role in the Pathogenesis and Regulation by Gut Microbiome. Mediators of Inflammation, 2015, 2015, 1-7. | 1.4 | 40 |
| 277 | Expert Recommendations on Treating Psoriasis in Special Circumstances. Actas Dermo-sifiligráficas, 2015, 106, 292-309. | 0.2 | 1 |
| 278 | Biologic Agents for Psoriasis. , 2015, , 1411-1420. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 279 | The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. <i>Journal of Dermatological Treatment</i> , 2015, 26, 23-31. | 1.1 | 173 |
| 280 | Psoriasis. <i>Lancet</i> , The, 2015, 386, 983-994. | 6.3 | 1,793 |
| 281 | Interventions for guttate psoriasis. <i>The Cochrane Library</i> , 2015, , . | 1.5 | 2 |
| 282 | Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden. <i>BioDrugs</i> , 2015, 29, 389-398. | 2.2 | 10 |
| 283 | Saudi practical guidelines on biologic treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 223-229. | 1.1 | 16 |
| 284 | Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 589-598. | 0.6 | 54 |
| 285 | Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 292-309. | 0.2 | 9 |
| 286 | Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 353-360. | 1.3 | 75 |
| 287 | The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blind randomized controlled trial. <i>International Journal of Dermatology</i> , 2015, 54, 95-101. | 0.5 | 36 |
| 288 | Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. <i>Pharmacological Reviews</i> , 2015, 67, 280-309. | 7.1 | 266 |
| 289 | Association between Skin and Joint Involvement in Patients with Psoriatic Arthritis Treated with Adalimumab: Analysis of Data from a German Non-Interventional Study. <i>Dermatology</i> , 2015, 230, 213-221. | 0.9 | 4 |
| 290 | Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 400-409. | 0.6 | 472 |
| 291 | Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. <i>BMJ</i> , The, 2015, 350, h1269-h1269. | 3.0 | 98 |
| 292 | Treatment goals for psoriasis: Should PASI 90 become the standard of care?. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 155-157. | 0.2 | 34 |
| 293 | Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 968-977.e2. | 0.6 | 43 |
| 294 | Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic. <i>Journal of Dermatological Treatment</i> , 2015, 26, 493-501. | 1.1 | 21 |
| 295 | CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis. <i>JAMA Dermatology</i> , 2015, 151, 837. | 2.0 | 38 |
| 296 | Systemic pharmacological treatments for chronic plaque psoriasis. <i>The Cochrane Library</i> , 0, , . | 1.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 297 | Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis. <i>JAMA Dermatology</i> , 2015, 151, 616. | 2.0 | 75 |
| 298 | Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin Manifestations. <i>Journal of Rheumatology</i> , 2015, 42, 952-959. | 1.0 | 14 |
| 299 | Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 767-776. | 1.3 | 16 |
| 300 | Treatment goals for psoriasis: Should PASI 90 become the standard of care?. <i>Actas Dermo-sifilograficas</i> , 2015, 106, 155-157. | 0.2 | 43 |
| 301 | Efficacy and safety of emerging immunotherapies in psoriasis. <i>Immunotherapy</i> , 2015, 7, 119-133. | 1.0 | 18 |
| 302 | Systemic methotrexate for the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 553-563. | 1.3 | 43 |
| 303 | Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. <i>BioDrugs</i> , 2015, 29, 327-339. | 2.2 | 50 |
| 304 | Adalimumab: A Review in Chronic Plaque Psoriasis. <i>Drugs</i> , 2015, 75, 2119-2130. | 4.9 | 29 |
| 305 | Current and Future Oral Systemic Therapies for Psoriasis. <i>Dermatologic Clinics</i> , 2015, 33, 91-109. | 1.0 | 26 |
| 306 | Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice. <i>Journal of Dermatological Treatment</i> , 2015, 26, 49-53. | 1.1 | 15 |
| 307 | Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. <i>British Journal of Dermatology</i> , 2015, 172, 504-512. | 1.4 | 62 |
| 309 | Effectiveness of Biologic and Conventional Systemic Therapies in Adults with Chronic Plaque Psoriasis in Daily Practice: A Systematic Review. <i>Acta Dermato-Venereologica</i> , 2016, 96, 453-458. | 0.6 | 36 |
| 310 | Combination Therapies for Psoriasis. , 2016, , 171-179. | | 0 |
| 311 | Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2016, Volume 9, 347-355. | 0.8 | 11 |
| 313 | Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials. <i>PLoS ONE</i> , 2016, 11, e0153740. | 1.1 | 82 |
| 314 | Adalimumab: a review of the reference product and biosimilars. <i>Biosimilars (Auckland, New Zealand)</i> , 0, Volume 6, 29-44. | 0.4 | 13 |
| 315 | Mechanistic Insights Into Today's (and Tomorrow's) Treatments for Moderate-to-Severe Psoriasis. <i>Journal of the Dermatology Nurses' Association</i> , 2016, 8, 29-43. | 0.1 | 1 |
| 316 | Comparison of the Efficacy of Methotrexate and Narrow-Band Ultraviolet B for the Treatment of Plaque-Type Psoriasis. <i>American Journal of Therapeutics</i> , 2016, 23, e405-e410. | 0.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 317 | Tumour necrosis factor- $\hat{\pm}$ plays a significant role in the Aldara-induced skin inflammation in mice. <i>British Journal of Dermatology</i> , 2016, 174, 1011-1021. | 1.4 | 17 |
| 318 | Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. <i>Dermatology</i> , 2016, 232, 640-647. | 0.9 | 32 |
| 319 | Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. <i>RMD Open</i> , 2016, 2, e000154. | 1.8 | 21 |
| 320 | Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. <i>International Journal of Women's Dermatology</i> , 2016, 2, 151-153. | 1.1 | 12 |
| 322 | A critical appraisal of the assessment and management of psoriasis. <i>Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals</i> , 2016, 8, 72-78. | 0.0 | 0 |
| 323 | Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1584-1591. | 0.3 | 63 |
| 324 | Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 612-618.e6. | 0.6 | 48 |
| 325 | Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. <i>Dermatology</i> , 2016, 232, 385-406. | 0.9 | 39 |
| 326 | Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. <i>Acta Dermato-Venereologica</i> , 2016, 96, 23-28. | 0.6 | 39 |
| 327 | Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 740-746. | 0.6 | 20 |
| 328 | British Association of Dermatologists™ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. <i>British Journal of Dermatology</i> , 2016, 175, 23-44. | 1.4 | 86 |
| 329 | Insights on methotrexate in psoriatic disease. <i>Clinical Immunology</i> , 2016, 172, 61-64. | 1.4 | 10 |
| 330 | Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1753-1759. | 1.3 | 42 |
| 331 | Safety of secukinumab in the treatment of psoriasis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1413-1420. | 1.0 | 99 |
| 332 | What is the Standard of Treatment for Plantar Psoriasis?. <i>Journal of the American Podiatric Medical Association</i> , 2016, 106, 4-4. | 0.2 | 0 |
| 333 | Methotrexate in psoriasis under real-world conditions: long-term efficacy and tolerability. <i>British Journal of Dermatology</i> , 2016, 174, 1407-1410. | 1.4 | 11 |
| 334 | Topical and Systemic Therapies for Moderate-to-Severe Psoriasis. , 2016, , 253-266. | | 1 |
| 335 | Biologic Therapy for Psoriasis. , 2016, , 281-294. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 336 | A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 332-338. | 1.1 | 61 |
| 337 | Treatment of psoriasis. , 2016, , 43-84. | | 0 |
| 338 | The spectrum of nephrocutaneous diseases and associations. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 247-270. | 0.6 | 5 |
| 339 | Secukinumab (AIN-457) for the treatment of Psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 187-202. | 1.3 | 10 |
| 340 | Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study. <i>Journal of Dermatology</i> , 2016, 43, 869-880. | 0.6 | 79 |
| 341 | British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015. <i>British Journal of Dermatology</i> , 2016, 174, 24-55. | 1.4 | 79 |
| 342 | Persistence and failure rates of adalimumab monotherapy in biologic-naïve patients with psoriasis: A retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 575-577. | 0.6 | 4 |
| 343 | Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. <i>Rheumatology International</i> , 2016, 36, 603-612. | 1.5 | 54 |
| 344 | Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 79-86. | 3.3 | 21 |
| 345 | Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations. <i>Actas Dermo-sifiligráficas</i> , 2016, 107, 194-206. | 0.2 | 8 |
| 346 | Metotrexato en psoriasis moderada-grave: revisión de la literatura y recomendaciones de experto. <i>Actas Dermo-sifiligráficas</i> , 2016, 107, 194-206. | 0.2 | 37 |
| 347 | Secukinumab for treating plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 119-128. | 1.4 | 18 |
| 348 | A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 577-593. | 1.4 | 53 |
| 349 | Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment. <i>British Journal of Dermatology</i> , 2017, 176, 777-785. | 1.4 | 26 |
| 350 | Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. <i>British Journal of Dermatology</i> , 2017, 176, 594-603. | 1.4 | 55 |
| 351 | Psoriasis and the liver: problems, causes and course. <i>Australasian Journal of Dermatology</i> , 2017, 58, 194-199. | 0.4 | 14 |
| 352 | Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. <i>Trials</i> , 2017, 18, 52. | 0.7 | 15 |
| 353 | Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209 Behandlungsreihen in Österreich. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 309-318. | 0.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 354 | Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. <i>Journal of Immunology</i> , 2017, 198, 3809-3814. | 0.4 | 71 |
| 355 | Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1646-1654. | 0.3 | 108 |
| 356 | Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 40-49. | 6.3 | 120 |
| 357 | Adalimumab in paediatric psoriasis. <i>Lancet, The</i> , 2017, 390, 5-6. | 6.3 | 4 |
| 358 | Immunopathogenesis of Psoriasis. , 2017, , 373-395. | | 4 |
| 359 | Biologic Therapy in the Treatment of Chronic Skin Disorders. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 315-327. | 0.7 | 2 |
| 360 | Taiwanese Dermatological Association consensus statement on management of psoriasis. <i>Dermatologica Sinica</i> , 2017, 35, 66-77. | 0.2 | 27 |
| 361 | Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1093-1102. | 0.6 | 110 |
| 362 | Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 70-85. | 2.3 | 7 |
| 363 | Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 2S-40S. | 0.6 | 9 |
| 364 | Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 1030-1037. | 0.6 | 4 |
| 365 | New biologics in psoriasis “ progress and problems. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1577-1578. | 1.3 | 5 |
| 366 | Digestive system in psoriasis: an update. <i>Archives of Dermatological Research</i> , 2017, 309, 679-693. | 1.1 | 38 |
| 367 | Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. <i>JAMA Dermatology</i> , 2017, 153, 1147. | 2.0 | 75 |
| 368 | Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. <i>Journal of Medical Economics</i> , 2017, 20, 1224-1230. | 1.0 | 23 |
| 369 | Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). <i>Journal of Dermatological Treatment</i> , 2017, 28, 394-400. | 1.1 | 11 |
| 370 | Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. <i>Journal of Autoimmunity</i> , 2017, 76, 21-37. | 3.0 | 94 |
| 371 | Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Drugs in R and D</i> , 2017, 17, 29-51. | 1.1 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 372 | Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 89-95. | 1.3 | 75 |
| 373 | Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2017, 176, 890-901. | 1.4 | 107 |
| 374 | Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. <i>Annual Review of Medicine</i> , 2017, 68, 255-269. | 5.0 | 134 |
| 375 | Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 207-222. | 1.3 | 5 |
| 376 | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2017, 12, CD011535. | 1.5 | 164 |
| 377 | Unerwünschte Wirkungen von Biologika bei Psoriasis. <i>Karger Kompass Dermatologie</i> , 2017, 5, 195-199. | 0.0 | 1 |
| 378 | Old and New Biological Therapies for Psoriasis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2297. | 1.8 | 179 |
| 379 | Characterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy. <i>European Journal of Dermatology</i> , 2017, 27, 579-589. | 0.3 | 2 |
| 380 | The Use of Apremilast to Treat Psoriasis During Deployment. <i>Military Medicine</i> , 2017, 182, 1628-1631. | 0.4 | 3 |
| 381 | Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 583-589. | 0.5 | 9 |
| 382 | Pathogenic Role of Cytokines and Effect of Their Inhibition in Psoriasis. , 0, , . | | 6 |
| 383 | Effectiveness of and factors associated with clinical response to methotrexate under daily life conditions in Asian patients with psoriasis: A retrospective cohort study. <i>Journal of Dermatology</i> , 2018, 45, 540-545. | 0.6 | 9 |
| 384 | Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 277-286.e10. | 0.6 | 163 |
| 385 | Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. <i>Current Medical Research and Opinion</i> , 2018, 34, 1325-1333. | 0.9 | 27 |
| 386 | Infectious risk of biological drugs vs. traditional systemic treatments in moderate-to-severe psoriasis: a cohort analysis in the French insurance database. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 436-449. | 1.0 | 10 |
| 387 | Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis. <i>Molecular Pain</i> , 2018, 14, 174480691876220. | 1.0 | 12 |
| 388 | Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 135-144.e7. | 0.6 | 46 |
| 389 | Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 437-447. | 3.3 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 390 | Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology and Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients. <i>Current Rheumatology Reports</i> , 2018, 20, 1. | 2.1 | 31 |
| 391 | Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 383-394. | 0.6 | 69 |
| 392 | The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 557-568. | 1.1 | 35 |
| 393 | Pharmacoeconomics of Systemic and Biologic Therapy in Dermatology. , 2018, , 83-91. | | 1 |
| 394 | Tumor Necrosis Factor Inhibition. , 2018, , 111-121. | | 0 |
| 395 | Systemic Therapies in Psoriasis. , 2018, , 145-158. | | 0 |
| 396 | Biological Agents in Pediatric Dermatology. , 2018, , 267-271. | | 0 |
| 397 | Utilization of Biologic and Systemic Agents in the Elderly. , 2018, , 281-294. | | 0 |
| 398 | Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian-frequentist approach. <i>Biometrical Journal</i> , 2018, 60, 564-582. | 0.6 | 10 |
| 399 | Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. <i>JAMA Dermatology</i> , 2018, 154, 581. | 2.0 | 74 |
| 400 | Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. <i>Dermatology and Therapy</i> , 2018, 8, 173-194. | 1.4 | 45 |
| 401 | Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1297-1304. | 1.3 | 12 |
| 402 | Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 90-99.e1. | 0.6 | 64 |
| 403 | Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials. <i>Value in Health</i> , 2018, 21, 1-8. | 0.1 | 18 |
| 404 | Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. <i>Journal of Dermatological Treatment</i> , 2018, 29, 334-346. | 1.1 | 39 |
| 405 | Adverse Reactions to Biologics in Psoriasis. <i>Current Problems in Dermatology</i> , 2018, 53, 1-14. | 0.8 | 20 |
| 406 | Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 515-528. | 1.3 | 15 |
| 407 | Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 405-423. | 3.3 | 72 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 408 | Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 295-311. | 2.9 | 57 |
| 409 | Opportunities and challenges in the treatment of psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 440-452. | 1.4 | 11 |
| 410 | Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom. <i>Cogent Medicine</i> , 2018, 5, 1495593. | 0.7 | 4 |
| 411 | Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1037-1051. | 0.6 | 29 |
| 412 | Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. <i>New England Journal of Medicine</i> , 2018, 379, 1313-1321. | 13.9 | 301 |
| 413 | Oral Agents for Psoriasis. <i>Updates in Clinical Dermatology</i> , 2018, , 55-71. | 0.1 | 0 |
| 414 | Biologics. <i>Updates in Clinical Dermatology</i> , 2018, , 73-92. | 0.1 | 0 |
| 416 | Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018, 20, 57. | 2.1 | 53 |
| 417 | Disease Modification in Psoriatic Arthritis. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 197-213. | 0.6 | 0 |
| 418 | Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. <i>British Journal of Dermatology</i> , 2018, 179, 623-631. | 1.4 | 112 |
| 419 | Disseminated tuberculosis following adalimumab treatment in psoriasis despite negative screening. <i>International Journal of Dermatology</i> , 2019, 58, 98-100. | 0.5 | 6 |
| 420 | Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 42-55. | 1.3 | 7 |
| 421 | Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 923-930. | 0.6 | 11 |
| 422 | Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis. <i>Dermatologic Therapy</i> , 2019, 32, e13051. | 0.8 | 15 |
| 423 | Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. <i>PLoS ONE</i> , 2019, 14, e0220868. | 1.1 | 118 |
| 424 | Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase 3, randomized, placebo-controlled trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2168-2178. | 1.3 | 28 |
| 425 | Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis <sc>SOLAPSO</sc> â€“ Sociedad Latinoamericana de Psoriasis <i>(Latin American Psoriasis) Tj ETQq0 0 0 rgBT 0 Overlock 10 Tf 50 97 | 0.5 | 16 |
| 426 | Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 576-586. | 6.3 | 198 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 427 | Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1380. | 2.0 | 5 |
| 428 | Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children. <i>Children</i> , 2019, 6, 108. | 0.6 | 31 |
| 429 | Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis. <i>JAMA Dermatology</i> , 2019, 155, 327. | 2.0 | 19 |
| 430 | An update on clinical safety of adalimumab in treating psoriasis: A systematic review and meta-analysis based on 20 randomized controlled trials. <i>Journal of Cosmetic Dermatology</i> , 2019, 18, 1550-1559. | 0.8 | 2 |
| 431 | State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. <i>Current Opinion in Pharmacology</i> , 2019, 46, 90-99. | 1.7 | 34 |
| 432 | VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn's disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand. <i>Current Medical Research and Opinion</i> , 2019, 35, 1837-1846. | 0.9 | 6 |
| 433 | Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 76-107. | 0.5 | 23 |
| 434 | Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis. <i>International Immunopharmacology</i> , 2019, 73, 442-450. | 1.7 | 20 |
| 435 | Psoriasis in moderate grave plaque - immunobiological treatment. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 493-508. | 0.3 | 1 |
| 436 | Moderate to severe plaque psoriasis - treatment with drugs of the classic scheme. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 530-534. | 0.3 | 0 |
| 437 | Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. <i>BioDrugs</i> , 2019, 33, 241-253. | 2.2 | 34 |
| 438 | Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. <i>British Journal of Dermatology</i> , 2019, 181, 1177-1189. | 1.4 | 28 |
| 439 | Psoriasis Pathogenesis and Treatment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1475. | 1.8 | 1,004 |
| 440 | Monocytes/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation. <i>Scientific Reports</i> , 2019, 9, 5310. | 1.6 | 42 |
| 441 | Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. <i>RMD Open</i> , 2019, 5, e000763. | 1.8 | 27 |
| 442 | Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1029-1072. | 0.6 | 542 |
| 443 | Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis. <i>The Cochrane Library</i> , 2019, 2019, CD011541. | 1.5 | 6 |
| 444 | Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 76-85. | 1.4 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 445 | Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 15. | 1.0 | 65 |
| 446 | Psoriasis: Which therapy for which patient. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 27-40. | 0.6 | 271 |
| 447 | 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 31-58. | 0.3 | 12 |
| 448 | Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 81-92. | 0.3 | 18 |
| 449 | 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32. | 2.9 | 312 |
| 450 | 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29. | 1.5 | 264 |
| 451 | Review of safety and efficacy of approved systemic psoriasis therapies. <i>International Journal of Dermatology</i> , 2019, 58, 649-658. | 0.5 | 66 |
| 452 | <sc>AURIEL</sc> â€œPsO: a randomized, double-blind phase <sc>III</sc> equivalence trial to demonstrate the clinical similarity of the proposed biosimilar <sc>MSB</sc> 11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 316-326. | 1.4 | 41 |
| 453 | Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast and methotrexate-naïve patients in the French National Health Insurance database. <i>British Journal of Dermatology</i> , 2020, 182, 690-697. | 1.4 | 18 |
| 454 | Biologics for chronic inflammatory skin diseases: an update for the clinician. <i>Journal of Dermatological Treatment</i> , 2020, 31, 108-130. | 1.1 | 17 |
| 455 | The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 213-221. | 1.1 | 13 |
| 456 | Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 412-424. | 0.6 | 12 |
| 457 | Real-world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 525-532. | 1.3 | 12 |
| 458 | A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. <i>British Journal of Dermatology</i> , 2020, 182, 869-879. | 1.4 | 31 |
| 459 | Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses. <i>Dermatology and Therapy</i> , 2020, 10, 73-86. | 1.4 | 38 |
| 460 | Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 435-442. | 2.3 | 14 |
| 461 | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 1, CD011535. | 1.5 | 86 |
| 462 | Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1138-1149. | 0.6 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 463 | A cost-effectiveness and budget impact analysis of apremilast in patients with psoriasis in the Italian setting. <i>Journal of Medical Economics</i> , 2020, 23, 362-370. | 1.0 | 1 |
| 464 | Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. <i>Advances in Therapy</i> , 2020, 37, 364-380. | 1.3 | 51 |
| 465 | Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis. <i>Rheumatology</i> , 2020, 59, 3657-3665. | 0.9 | 2 |
| 466 | The TNF/IL-23/IL-17 axis: Head-to-head trials comparing different biologics in psoriasis treatment. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12946. | 1.3 | 58 |
| 467 | Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2021, 237, 158-165. | 0.9 | 3 |
| 468 | Hydrogel-Based Active Substance Release Systems for Cosmetology and Dermatology Application: A Review. <i>Pharmaceutics</i> , 2020, 12, 396. | 2.0 | 71 |
| 469 | Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations. <i>Current Obesity Reports</i> , 2020, 9, 165-178. | 3.5 | 57 |
| 470 | Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1945. | 3.8 | 953 |
| 471 | Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , 2020, 33, e13687. | 0.8 | 45 |
| 472 | Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 737-750. | 0.6 | 3 |
| 473 | Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 211-232. | 1.3 | 12 |
| 474 | Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 517-527. | 0.8 | 22 |
| 475 | Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. <i>Journal of Dermatological Treatment</i> , 2020, 31, 470-475. | 1.1 | 30 |
| 476 | Patient sex does not affect endoscopic outcomes of biologics in inflammatory bowel disease but is associated with adverse events. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1489-1500. | 1.0 | 3 |
| 477 | Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 561-572. | 0.6 | 5 |
| 478 | Joint American Academy of Dermatology and National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1445-1486. | 0.6 | 184 |
| 479 | United States systemic psoriasis treatments: increases in the use of biologic agents and plateau of methotrexate and oral small molecule inhibitors. <i>Journal of Dermatological Treatment</i> , 2022, 33, 143-145. | 1.1 | 8 |
| 480 | In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-4. | 1.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 481 | Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation. Expert Opinion on Drug Safety, 2020, 19, 433-438. | 1.0 | 12 |
| 482 | Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times. Dermatology and Therapy, 2020, 10, 339-349. | 1.4 | 37 |
| 483 | Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 135-142. | 1.3 | 29 |
| 484 | Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review. Dermatologic Therapy, 2021, 34, e14498. | 0.8 | 20 |
| 486 | Tumor Necrosis Factor Inhibitors. , 2021, , 287-301.e7. | | 2 |
| 487 | Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. Expert Opinion on Biological Therapy, 2021, 21, 87-96. | 1.4 | 12 |
| 488 | The Role of Leptin in the Association between Obesity and Psoriasis. Biomolecules and Therapeutics, 2021, 29, 11-21. | 1.1 | 26 |
| 489 | PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. Journal of Dermatological Treatment, 2022, 33, 1661-1669. | 1.1 | 15 |
| 490 | Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values $\geq 1, 2, 3$ or 5 derived from a statistical conversion method. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1161-1175. | 1.3 | 13 |
| 491 | Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy, 2021, 11, 885-905. | 1.4 | 40 |
| 492 | Azathioprine weekly pulse versus methotrexate for the treatment of chronic plaque psoriasis: A randomized controlled trial. Indian Journal of Dermatology, Venereology and Leprology, 2021, 87, 1-6. | 0.2 | 5 |
| 493 | Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Rheumatology, The, 2021, 3, e204-e213. | 2.2 | 15 |
| 494 | Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects. Clinical Pharmacology in Drug Development, 2021, 10, 1166-1173. | 0.8 | 2 |
| 495 | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. The Cochrane Library, 2021, 2021, CD011535. | 1.5 | 34 |
| 496 | Psoriasis. Lancet, The, 2021, 397, 1301-1315. | 6.3 | 792 |
| 497 | Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules. Frontiers in Pharmacology, 2021, 12, 586827. | 1.6 | 6 |
| 498 | An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability. Drug Design, Development and Therapy, 2021, Volume 15, 2987-2998. | 2.0 | 8 |
| 500 | The safety profile of biologic agents in comparison with non-biologic systemic agents, and topical compounds in the management of psoriasis – a 30-month prospective, observational cohort study. International Journal of Clinical Practice, 2021, , e14915. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 501 | Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 572-581. | 0.6 | 36 |
| 502 | Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2021, 11, 1965-1998. | 1.4 | 14 |
| 503 | Psoriasis and Cardiovascular Disease: A Narrative Review. <i>Korean Journal of Family Medicine</i> , 2021, 42, 345-355. | 0.4 | 11 |
| 504 | New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2328-2337. | 0.3 | 21 |
| 505 | Treatments in psoriasis: from standard pharmacotherapy to nanotechnology therapy. <i>Postepy Dermatologii i Alergologii</i> , 2022, 39, 460-471. | 0.4 | 8 |
| 506 | Biologics in pediatric dermatology. <i>Indian Journal of Paediatric Dermatology</i> , 2021, 22, 107. | 0.0 | 0 |
| 508 | First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq. <i>Dermatology</i> , 2021, 237, 338-346. | 0.9 | 5 |
| 509 | Comparison of Biologics and Oral Treatments for Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 258. | 2.0 | 169 |
| 511 | Statistical Models and Methods for Incomplete Data in Randomized Clinical Trials. , 2014, , 1-27. | | 2 |
| 512 | Targeted Therapies and Biomarkers for Personalized Treatment of Psoriasis. , 2015, , 77-100. | | 2 |
| 513 | Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 91-97. | 1.6 | 18 |
| 514 | Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial. <i>Sovremennaya Revmatologiya</i> , 2018, 12, 71-84. | 0.1 | 3 |
| 515 | Biological therapies in psoriasis - revisited. <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , 2018, 56, 75-84. | 0.3 | 4 |
| 516 | Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2010, 3, 49. | 0.8 | 3 |
| 517 | Personalized Medicine in Psoriasis: Concept and Applications. <i>Current Vascular Pharmacology</i> , 2010, 8, 432-436. | 0.8 | 8 |
| 518 | Emerging Pathophysiological Targets of Psoriasis for Future Therapeutic Strategies. <i>Infectious Disorders - Drug Targets</i> , 2020, 20, 409-422. | 0.4 | 4 |
| 519 | Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2017, 21, 1-244. | 1.3 | 16 |
| 520 | Recombinant programmed cell death 1 inhibits psoriatic inflammation in imiquimod-treated mice. <i>International Journal of Molecular Medicine</i> , 2020, 46, 869-879. | 1.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 522 | Toxic epidermal necrolysis like reaction due to low-dose methotrexate in a case of cutaneous lupus erythematosus: A rare occurrence. Indian Journal of Dermatology, 2016, 61, 102. | 0.1 | 4 |
| 523 | Biological therapy of psoriasis. Indian Journal of Dermatology, 2010, 55, 161. | 0.1 | 36 |
| 524 | Randomized placebo control study of metformin in psoriasis patients with metabolic syndrome (systemic treatment cohort). Indian Journal of Endocrinology and Metabolism, 2017, 21, 581. | 0.2 | 17 |
| 525 | Kasr Al-Ainy's psoriasis unit protocol for the management of psoriasis, part I: topical and systemic therapies. Journal of the Egyptian Women's Dermatologic Society, 2019, 16, 1. | 0.2 | 1 |
| 526 | The use of biologics for severe psoriasis. Journal of the Korean Medical Association, 2015, 58, 917. | 0.1 | 3 |
| 528 | Adalimumab for the treatment of psoriasis. Expert Review of Dermatology, 2009, 4, 15-21. | 0.3 | 1 |
| 529 | Management of Psoriasis. Southern Medical Journal, 2009, 102, 631-636. | 0.3 | 0 |
| 531 | Neueste Erkenntnisse und Blick in die Zukunft. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2011, , 1-48. | 0.0 | 0 |
| 532 | Results of Combining Phosphorylase Kinase Inhibition with Removal of Precipitating Factors in Large Cohort of Psoriatic Patients: A Proof of Concept Study. Journal of Cosmetics Dermatological Sciences and Applications, 2011, 01, 79-94. | 0.1 | 1 |
| 534 | NORMAS DE BOA PRÁTICA PARA O TRATAMENTO DA PSORÍASE EM PLACAS EM IDADE NÃO PEDIÁTRICA COM BIOLÓGICOS. Journal of the Portuguese Society of Dermatology and Venereology, 2011, 69, 532. | 0.0 | 2 |
| 535 | Add-on Effects of Calcipotriol (Dovonex [®]) Ointment on Skin Symptoms and Adherence in Patients with Chronic Plaque Psoriasis. Nishinon Journal of Dermatology, 2012, 74, 189-193. | 0.0 | 0 |
| 536 | Biotech on the Rise: The Treatment of Psoriasis with Biological Drugs. , 0, , . | | 0 |
| 537 | Schwere Psoriasis – immer Biologics?*. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 6-11. | 0.0 | 0 |
| 539 | Biologics in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method. Journal of Pharmaceutical Care & Health Systems, 2016, 1, . | 0.1 | 0 |
| 540 | Plaque Psoriasis: Understanding Risk Factors of This Inflammatory Skin Pathology. Journal of Cosmetics Dermatological Sciences and Applications, 2016, 06, 67-80. | 0.1 | 2 |
| 541 | Coal tar to biologic: Search for ideal therapy for psoriasis continues. Clinical Dermatology Review, 2017, 1, 1. | 0.2 | 1 |
| 542 | Coal tar to biologic: Search for ideal therapy for psoriasis continues. Clinical Dermatology Review, 2017, 1, 1. | 0.2 | 0 |
| 543 | Clinical experience of combination therapy of infliximab and total glucosides of paeony for severe psoriasis with liver disorder history. Trends in Immunotherapy, 2017, 1, . | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 544 | Humira still has a lot to offer. <i>Dermatologie Pro Praxi</i> , 2019, 13, 34-44. | 0.1 | 0 |
| 545 | Recent recommendations on psoriatic arthritis treatment in accordance with 2018 American College of Rheumatology and National Psoriasis Foundation guidelines. <i>Bol. S. Sustavy, PozvonoÅnik</i> , 2019, 9, 46-58. | 0.1 | 0 |
| 546 | Inflammatory Arthritis: Psoriatic Arthritis. , 2020, , 697-704. | | 0 |
| 547 | Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple treatments meta-analysis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 47-56. | 0.4 | 12 |
| 548 | Viva voce: Adalimumab. <i>Indian Journal of Drugs in Dermatology</i> , 2020, 6, 53. | 0.0 | 0 |
| 549 | A preliminary prospective non-randomized controlled trial to compare the efficacy of subcutaneous etanercept versus oral methotrexate in moderate-to-severe chronic plaque psoriasis and correlation of response with T helper (th) 1, th2, th17 and T regulatory cytokine patterns. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2020, 86, 441. | 0.2 | 0 |
| 550 | How current biologic therapies affect the risk of major adverse cardiovascular events in patients with plaque psoriasis? A systematic review and meta-analysis of randomized controlled trials. <i>Postepy Dermatologii I Alergologii</i> , 2020, 37, 986-994. | 0.4 | 2 |
| 551 | Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis. <i>Frontiers in Pharmacology</i> , 2021, 12, 774808. | 1.6 | 16 |
| 552 | Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. <i>Journal of Dermatology</i> , 2022, 49, 95-105. | 0.6 | 11 |
| 553 | Tofacitinib for the treatment of psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 400-410. | 0.8 | 9 |
| 554 | Evolution of immunotherapy methods for psoriasis and psoriatic arthritis: from total immunosuppression to selective treatment of therapeutic targets. <i>Medical Alphabet</i> , 2020, , 15-21. | 0.0 | 0 |
| 555 | Adalimumab for Psoriasis. , 2021, , 153-172. | | 0 |
| 556 | Systemic treatment of psoriasis: from methotrexate to biologics. <i>Vestnik Dermatologii I Venerologii</i> , 2020, 96, 7-26. | 0.2 | 6 |
| 557 | Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. <i>Biologics: Targets and Therapy</i> , 2009, 3, 303-18. | 3.0 | 19 |
| 558 | Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, 16-24. | 0.1 | 24 |
| 559 | New Oral Therapies for Psoriasis: A Comprehensive Review. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 25-8. | 0.1 | 48 |
| 560 | Psoriasis and Psoriatic Arthritis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2017, 10, S16-S25. | 0.1 | 3 |
| 561 | Diagnosis and management of psoriasis. <i>Canadian Family Physician</i> , 2017, 63, 278-285. | 0.1 | 173 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 562 | Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 988-94. | 0.4 | 6 |
| 563 | Current Developments in the Immunology of Psoriasis. <i>Yale Journal of Biology and Medicine</i> , 2020, 93, 97-110. | 0.2 | 56 |
| 564 | Real-life Efficacy and Safety of Biosimilar Adalimumab (ZRC-3197) in Patients with Plaque Psoriasis: A Tertiary Care Center Experience. <i>Indian Dermatology Online Journal</i> , 2020, 11, 182-186. | 0.2 | 0 |
| 565 | Home Narrowband Ultraviolet B Phototherapy for Photoresponsive Skin Conditions: A Health Technology Assessment. <i>Ontario Health Technology Assessment Series</i> , 2020, 20, 1-134. | 3.0 | 1 |
| 566 | Understanding Superiority, Noninferiority, and Equivalence for Clinical Trials. <i>Indian Dermatology Online Journal</i> , 2020, 11, 890-894. | 0.2 | 0 |
| 567 | Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. <i>Advances in Therapy</i> , 2022, 39, 583-597. | 1.3 | 4 |
| 568 | Understanding superiority, noninferiority, and equivalence for clinical trials. <i>Indian Dermatology Online Journal</i> , 2020, 11, 890. | 0.2 | 5 |
| 569 | Real-life efficacy and safety of biosimilar adalimumab (ZRC-3197) in patients with plaque psoriasis: A tertiary care center experience. <i>Indian Dermatology Online Journal</i> , 2020, 11, 182. | 0.2 | 1 |
| 570 | Comparison of the clinical efficacy of subcutaneous vs. oral administration of methotrexate in patients with psoriasis vulgaris: a Randomized controlled trial. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 942-948. | 0.6 | 5 |
| 571 | Canadian Adalimumab Post-Marketing Observational Epidemiological Study Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-Month Results of Comparative Effectiveness of Adalimumab and nbDMARDs. <i>Journal of Rheumatology</i> , 2022, , jrheum.200609. | 1.0 | 0 |
| 572 | Racial/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review. <i>Archives of Dermatological Research</i> , 2023, 315, 41-50. | 1.1 | 7 |
| 574 | Choosing the right biologic for complications of inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 235-249. | 1.4 | 3 |
| 575 | Pharmacoeconomic aspects of treatment of psoriasis with biological drugs. <i>Vestnik Dermatologii i Venerologii</i> , 2012, 88, 26-31. | 0.2 | 1 |
| 576 | [Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. <i>Actas Dermo-sifiligráficas</i> . 2022, 113, T261-T277. | 0.2 | 4 |
| 577 | Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial. <i>PLoS ONE</i> , 2022, 17, e0263214. | 1.1 | 2 |
| 579 | Clinical and economic analysis of administering ustekinumab(stelara) to patients with severe psoriasis. <i>Vestnik Dermatologii i Venerologii</i> , 2011, 87, 63-70. | 0.2 | 0 |
| 580 | Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis. <i>Advances in Therapy</i> , 2022, 39, 2256-2269. | 1.3 | 10 |
| 581 | Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS). <i>Dermatology and Therapy</i> , 2022, , 1. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 582 | Immunobiologicals in dermatology. Anais Brasileiros De Dermatologia, 2022, , . | 0.5 | 1 |
| 583 | Comparative effectiveness of Adalimumab versus Ustekinumab in the treatment of severe chronic plaque psoriasis: the results based on data from the Program "Treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland. Dermatologic Therapy, 2022, , e15481. | 0.8 | 0 |
| 584 | Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis. Chinese Medical Journal, 2022, 135, 11-19. | 0.9 | 4 |
| 586 | A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy. Sovremennaya Revmatologiya, 2021, 15, 106-110. | 0.1 | 0 |
| 587 | Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis. Expert Opinion on Biological Therapy, 2022, 22, 1579-1584. | 1.4 | 6 |
| 588 | Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics: Targets and Therapy, 2009, 3, 303. | 3.0 | 9 |
| 589 | Comparative Effectiveness and Safety of Methotrexate Versus PUVA in Severe Chronic Stable Plaque Psoriasis. Indian Journal of Dermatology, 2021, 66, 371-377. | 0.1 | 2 |
| 590 | The Combined Use of Metformin and Methotrexate in Psoriasis Patients with Metabolic Syndrome. Dermatology Research and Practice, 2022, 2022, 1-7. | 0.3 | 1 |
| 591 | Tumor necrosis factor (TNF) inhibitors. , 2013, , 307-318.e4. | | 1 |
| 593 | Methotrexate: Revisited efficiency and safety of drug administration in psoriasis patients. Vestnik Dermatologii i Venerologii, 2017, 93, 38-45. | 0.2 | 1 |
| 594 | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. The Cochrane Library, 2022, 2022, . | 1.5 | 25 |
| 596 | 4â€fThe psoriasiform reaction pattern. , 2010, , 49-67. | | 0 |
| 597 | Case Report: A Case Series of Immunobiological Therapy (Anti-TNF-Î±) for Patients With Erythema Nodosum Leprosum. Frontiers in Medicine, 0, 9, . | 1.2 | 3 |
| 598 | Pathogenesis-oriented therapy of psoriasis using biologics. Expert Opinion on Biological Therapy, 2022, 22, 1463-1473. | 1.4 | 6 |
| 599 | Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20â€year systematic review and metaâ€analysis of randomized controlled trials. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2301-2315. | 1.3 | 1 |
| 600 | Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Clinical Practice, 2022, 2022, 1-11. | 0.8 | 5 |
| 601 | Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis. Frontiers in Medicine, 0, 9, . | 1.2 | 5 |
| 602 | Increasing to weekly adalimumab dosing leads to improved psoriasis outcomesâ€”A retrospective singleâ€centre review of realâ€world data. Journal of the European Academy of Dermatology and Venereology, 2023, 37, . | 1.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 603 | The Changing Landscape of Psoriasis: New Horizons for Oral Therapies. EMJ Dermatology, 0, , 2-9. | 0.0 | 0 |
| 604 | Is Complete Skin Clearance in Psoriasis the Answer?. EMJ Dermatology, 0, , 53-61. | 0.0 | 0 |
| 605 | Tumor necrosis factor- α inhibitor-induced morphea and psoriasiform dermatitis in a pediatric patient with Crohn's disease. Pediatric Dermatology, 0, , . | 0.5 | 2 |
| 606 | Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. British Journal of Dermatology, 2023, 188, 618-627. | 1.4 | 5 |
| 607 | Economic Evaluation of Selected Interleukin Inhibitors Versus Methotrexate for Moderate-to-Severe Plaque Psoriasis From the Philippine Payer Perspective. Value in Health Regional Issues, 2023, 34, 100-107. | 0.5 | 1 |
| 608 | Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Seminars in Arthritis and Rheumatism, 2023, 59, 152165. | 1.6 | 3 |
| 609 | ANALYSIS OF THE EFFICACY AND SAFETY OF GENETICALLY ENGINEERED BIOLOGICAL THERAPY FOR MODERATELY SEVERE AND SEVERE FORMS OF PSORIASIS. , 2022, 19, 3-9. | | 0 |
| 610 | Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta-analysis of randomized controlled trials. International Journal of Rheumatic Diseases, 2023, 26, 625-637. | 0.9 | 4 |
| 611 | Conventional therapy in psoriasis. Lost in translation?. British Journal of Dermatology, 2023, 188, 589-590. | 1.4 | 0 |
| 612 | Drug survival of methotrexate and predictor factors for discontinuation in psoriasis. International Journal of Dermatology, 2023, 62, 649-656. | 0.5 | 2 |
| 625 | Biologic Agents for Psoriasis. , 2023, , 1595-1606. | | 0 |
| 630 | Doit-on prescrire du méthotrexate dans le rhumatisme psoriasique? , 2023, , 175-185. | | 0 |
| 631 | Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis. Clinical Pharmacokinetics, 2024, 63, 137-153. | 1.6 | 0 |